Catalog No.
YHG52001
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Glu296-Ser598
Predicted molecular weight
36.45 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q13421
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
CAK1 antigen, Mesothelin, MSLN, Pre-pro-megakaryocyte-potentiating factor, MPF
Neuroinflammation Markers in Tear Fluid of Mild Alzheimer's Disease., PMID:40471493
Disrupted MOS signaling alters meiotic cell cycle regulation and the egg transcriptome., PMID:40424049
B4M3 CAR-T cell enhance antitumor activity and non-tumor toxicity in ovarian cancer., PMID:40414070
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266
[Preliminary study of mesothelin-loaded paclitaxel nanoparticles for ultrasound molecular imaging and treatment of ovarian cancer]., PMID:40375590
Enhancing mesothelin CAR T cell therapy for pancreatic cancer with an oncolytic herpes virus boosting CAR target antigen expression., PMID:40366419
ERC/Mesothelin Is Associated with the Formation of Microvilli on the Mesothelium and Has Limited Functional Relevance Under Physiological Conditions., PMID:40362566
Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma., PMID:40362535
PDZ domains of PATJ facilitate immunological synapse formation to promote T cell activation., PMID:40341028
Development and optimization of Eva1 (MPZL2) targeting chimeric antigen receptor T cells., PMID:40341026
Restoration of TP53 strategy via specific nanoparticles for ovarian cancer therapy., PMID:40325478
Robust differentiation of NK cells from MSLN.CAR-IL-15-engineered human iPSCs with enhanced antitumor efficacy against solid tumors., PMID:40315330
Chimeric antigen receptor NK cells for breast cancer immunotherapy., PMID:40305951
Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugation., PMID:40275270
Evaluating therapeutic plasma exchange and protease inhibitors as mechanisms to reduce soluble mesothelin., PMID:40240561
CAR T cells in lung cancer: Targeting tumor-associated antigens to revolutionize immunotherapy., PMID:40168775
Sodium citrate pretreatment enhances CAR-T cell persistence and anti-tumor efficacy through inhibition of calcium signaling., PMID:40165944
Selective activation of interleukin-2/interleukin-15 receptor signaling in tumor microenvironment using paired bispecific antibodies., PMID:40132909
CD4+ anti-TGF-β CAR T cells and CD8+ conventional CAR T cells exhibit synergistic antitumor effects., PMID:40107245
Serum proteomic profiling reveals potential predictive indicators for coronary artery calcification in stable ischemic heart disease., PMID:40106019
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager., PMID:40081946
Mesothelin (MSLN) is Highly Expressed in Triple Negative Breast Cancer and is Associated with Enhanced Cell Proliferation and Proinflammatory Tumor Microenvironment., PMID:40080368
Single-cell and spatial transcriptome profiling reveal CTHRC1+ fibroblasts promote EMT through WNT5A signaling in colorectal cancer., PMID:40050872
Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer., PMID:40033418
Targeting mesothelin-CD24 axis repolarizes tumor-associated macrophages to potentiate PD-1 blockade therapy in high-grade serous ovarian cancer., PMID:40010770
Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer., PMID:39995672
Revolutionizing pancreatic cancer treatment with CAR-T therapy., PMID:39978971
Targeting Mesothelin Enhances Personalized Neoantigen Vaccine Induced Antitumor Immune Response in Orthotopic Pancreatic Cancer Mouse Models., PMID:39887656
Development of a novel molecular probe for visualizing mesothelin on the tumor via positron emission tomography., PMID:39878895
Transplantation of the MSLN-deficient Thymus Generates MSLN Epitope Reactive T Cells to Attenuate Tumor Progression., PMID:39853704
Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial)., PMID:39836408
Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells., PMID:39809749
A humanized anti-MSLN×4-1BB bispecific antibody exhibits potent antitumour activity through 4-1BB signaling activation and fc function without systemic toxicity., PMID:39806351
Integrative multi-omics analysis reveals a novel subtype of hepatocellular carcinoma with biological and clinical relevance., PMID:39712016
Excess shed mesothelin disrupts pancreatic cancer cell clustering to impair peritoneal colonization., PMID:39673668
Endothelial Angpt2 Promotes Adipocyte Progenitor Cells Maturation to Increase Visceral Adipose Tissue Accumulation., PMID:39628006
Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer., PMID:39627822
Conditionally activated immunotoxins with prolonged half-life can enhance the anti-tumor activity., PMID:39603436
Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity., PMID:39576012
Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study., PMID:39548510
Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma., PMID:39542119
Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis., PMID:39511890
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis., PMID:39487859
Identification of a Novel Vascular Endothelial Growth Factor Receptor-3-Targeting Peptide for Molecular Imaging of Metastatic Lymph Nodes., PMID:39469784
Combination therapy of Sanjie Zhentong capsules for endometriosis: Impact on hormone regulation and serum expression of FOLR1 and MSLN., PMID:39465861
Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches., PMID:39453574
Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells., PMID:39433427
Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies., PMID:39431011
An innovative strategy harnessing self-activating CAR-NK cells to mitigate TGF-β1-driven immune suppression., PMID:39423512
Mesothelin- and nucleolin-specific T cells from combined short peptides effectively kill triple-negative breast cancer cells., PMID:39294656
For research use only. Not for human or drug use.
